409 related articles for article (PubMed ID: 33765180)
1. Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis.
Benn M; Emanuelsson F; Tybjærg-Hansen A; Nordestgaard BG
Diabetologia; 2021 Jul; 64(7):1492-1503. PubMed ID: 33765180
[TBL] [Abstract][Full Text] [Related]
2. Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.
Sacco S; Foschi M; Ornello R; De Santis F; Pofi R; Romoli M
Diabetologia; 2024 Jul; 67(7):1192-1205. PubMed ID: 38625582
[TBL] [Abstract][Full Text] [Related]
3. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
[TBL] [Abstract][Full Text] [Related]
4. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
5. Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database.
Rathmann W; Kostev K
Acta Diabetol; 2022 Nov; 59(11):1443-1451. PubMed ID: 35933524
[TBL] [Abstract][Full Text] [Related]
6. Diabetes drugs and stroke risk: Intensive versus conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials.
Lim S; Oh TJ; Dawson J; Sattar N
Diabetes Obes Metab; 2020 Jan; 22(1):6-15. PubMed ID: 31379119
[TBL] [Abstract][Full Text] [Related]
7. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Ferrannini E; DeFronzo RA
Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
[TBL] [Abstract][Full Text] [Related]
8. Hyperglycaemia, diabetes and risk of fragility fractures: observational and Mendelian randomisation studies.
Emanuelsson F; Afzal S; Jørgensen NR; Nordestgaard BG; Benn M
Diabetologia; 2024 Feb; 67(2):301-311. PubMed ID: 38095658
[TBL] [Abstract][Full Text] [Related]
9. Impact of glucose on risk of dementia: Mendelian randomisation studies in 115,875 individuals.
Benn M; Nordestgaard BG; Tybjærg-Hansen A; Frikke-Schmidt R
Diabetologia; 2020 Jun; 63(6):1151-1161. PubMed ID: 32172311
[TBL] [Abstract][Full Text] [Related]
10. Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.
Bonnet F; Scheen AJ
Diabetes Metab; 2017 Sep; 43(4):299-313. PubMed ID: 28522196
[TBL] [Abstract][Full Text] [Related]
11. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
12. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
Baviera M; Genovese S; Lepore V; Colacioppo P; Robusto F; Tettamanti M; D'Ettorre A; Avanzini F; Fortino I; Nicolucci A; Roncaglioni MC; Giorgino F
Diabetes Obes Metab; 2021 Jul; 23(7):1484-1495. PubMed ID: 33606897
[TBL] [Abstract][Full Text] [Related]
13. Contributions of elevated CRP, hyperglycaemia, and type 2 diabetes to cardiovascular risk in the general population: observational and Mendelian randomization studies.
Rolver MG; Emanuelsson F; Nordestgaard BG; Benn M
Cardiovasc Diabetol; 2024 May; 23(1):165. PubMed ID: 38730445
[TBL] [Abstract][Full Text] [Related]
14. The treament of hyperglycemia in acute ischemic stroke with incretin-based drugs.
Ferrari F; Moretti A; Villa RF
Pharmacol Res; 2020 Oct; 160():105018. PubMed ID: 32574826
[TBL] [Abstract][Full Text] [Related]
15. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
Lin DS; Lee JK; Hung CS; Chen WJ
Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
[TBL] [Abstract][Full Text] [Related]
17. Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis.
Li J; Ji C; Zhang W; Lan L; Ge W
J Diabetes Complications; 2023 Jan; 37(1):108362. PubMed ID: 36462459
[TBL] [Abstract][Full Text] [Related]
18. Relationship of Familial Hypercholesterolemia and High Low-Density Lipoprotein Cholesterol to Ischemic Stroke: Copenhagen General Population Study.
Beheshti S; Madsen CM; Varbo A; Benn M; Nordestgaard BG
Circulation; 2018 Aug; 138(6):578-589. PubMed ID: 29593013
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
20. Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis.
Gu S; Hu X; Shi L; Zhen X; Sun X; Huang M; Gu Y; Dong H
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
